Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Abdi, H., Zargar, H., Goldenberg, S. L., Walshe, T., Pourmalek, F., Eddy, C., . . . Black, P. C. (2015). Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. Urol Oncol, 33(4), 165.e161-167. doi:10.1016/j.urolonc.2015.01.004

Abdollah, F., Karnes, R. J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., . . . Briganti, A. (2014). Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol, 65(3), 554-562. doi:10.1016/j.eururo.2013.09.025

Abdollah, F., Karnes, R. J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., . . . Briganti, A. (2014). Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol, 32(35), 3939-3947. doi:10.1200/JCO.2013.54.7893

Abdollah, F., Suardi, N., Cozzarini, C., Gallina, A., Capitanio, U., Bianchi, M., . . . Briganti, A. (2013). Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol, 63(6), 998-1008. doi:10.1016/j.eururo.2012.10.036

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., . . . Scher, H. I. (2019). Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol, 5(4), 471-478. doi:10.1001/jamaoncol.2018.5801

Abughosh, Z., Margolick, J., Goldenberg, S. L., Taylor, S. A., Afshar, K., Bell, R., . . . Black, P. C. (2013). A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol, 189(4), 1326-1331. doi:10.1016/j.juro.2012.09.121

Ahlgren, G. M., Flodgren, P., Tammela, T. L. J., Kellokumpu-Lehtinen, P., Borre, M., Angelsen, A., . . . Sengelov, L. (2018). Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol, 73(6), 870-876. doi:10.1016/j.eururo.2018.01.012

Akaza, H., Hinotsu, S., Usami, M., Arai, Y., Kanetake, H., Naito, S., . . . Study Group for the Combined Androgen Blockade Therapy of Prostate, C. (2009). Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 115(15), 3437-3445. doi:10.1002/cncr.24395

Akbari, M. R., Wallis, C. J., Toi, A., Trachtenberg, J., Sun, P., Narod, S. A., & Nam, R. K. (2014). The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer, 111(6), 1238-1240. doi:10.1038/bjc.2014.428

Alanee, S. R., Glogowski, E. A., Schrader, K. A., Eastham, J. A., & Offit, K. (2014). Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed), 6, 15-30.

Allen, S., Kilian, C., Phelps, J., & Whelan, H. T. (2012). The use of hyperbaric oxygen for treating delayed radiation injuries in gynecologic malignancies: a review of literature and report of radiation injury incidence. Support Care Cancer, 20(10), 2467-2472. doi:10.1007/s00520-012-1379-x

Allott, E. H., Masko, E. M., & Freedland, S. J. (2013). Obesity and prostate cancer: weighing the evidence. Eur Urol, 63(5), 800-809. doi:10.1016/j.eururo.2012.11.013

Amini, A., Jones, B. L., Yeh, N., Rusthoven, C. G., Armstrong, H., & Kavanagh, B. D. (2015). Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. Int J Radiat Oncol Biol Phys, 93(5), 1052-1063. doi:10.1016/j.ijrobp.2015.09.006

Andreyev, H. J., Benton, B. E., Lalji, A., Norton, C., Mohammed, K., Gage, H., . . . Lindsay, J. O. (2013). Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet, 382(9910), 2084-2092. doi:10.1016/S0140-6736(13)61648-7

Andriole, G. L., Bostwick, D., Brawley, O. W., Gomella, L., Marberger, M., Montorsi, F., . . . Group, R. S. (2011). The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol, 185(1), 126-131. doi:10.1016/j.juro.2010.09.011

Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., . . . Group, R. S. (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med, 362(13), 1192-1202. doi:10.1056/NEJMoa0908127

Arnsrud Godtman, R., Holmberg, E., Lilja, H., Stranne, J., & Hugosson, J. (2015). Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol, 68(3), 354-360. doi:10.1016/j.eururo.2014.12.006

Astrom, L., Grusell, E., Sandin, F., Turesson, I., & Holmberg, L. (2018). Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer. Radiother Oncol, 127(1), 81-87. doi:10.1016/j.radonc.2017.12.025

Astrom, L., Sandin, F., & Holmberg, L. (2018). Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer. Radiother Oncol, 129(3), 561-566. doi:10.1016/j.radonc.2018.08.011

Aus, G., Becker, C., Franzen, S., Lilja, H., Lodding, P., & Hugosson, J. (2004). Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol, 45(2), 160-165.

Aus, G., Robinson, D., Rosell, J., Sandblom, G., Varenhorst, E., & South-East Region Prostate Cancer, G. (2005). Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer, 103(5), 943-951. doi:10.1002/cncr.20855

Azzouzi, A. R., Barret, E., Moore, C. M., Villers, A., Allen, C., Scherz, A., . . . Emberton, M. (2013). TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int, 112(6), 766-774. doi:10.1111/bju.12265

Azzouzi, A. R., Vincendeau, S., Barret, E., Cicco, A., Kleinclauss, F., van der Poel, H. G., . . . Emberton, M. (2017). Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol, 18(2), 181-191. doi:10.1016/s1470-2045(16)30661-1

Bang, S. L., & Almallah, Y. Z. (2016). The Impact of Post-radical Prostatectomy Urinary Incontinence on Sexual and Orgasmic Well-being of Patients. Urology, 89, 1-5. doi:10.1016/j.urology.2015.11.026

Bansal, D., Undela, K., D'Cruz, S., & Schifano, F. (2012). Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One, 7(10), e46691. doi:10.1371/journal.pone.0046691

Barkati, M., Williams, S. G., Foroudi, F., Tai, K. H., Chander, S., van Dyk, S., . . . Duchesne, G. M. (2012). High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys, 82(5), 1889-1896. doi:10.1016/j.ijrobp.2010.09.006

Barnas, J. L., Pierpaoli, S., Ladd, P., Valenzuela, R., Aviv, N., Parker, M., . . . Mulhall, J. P. (2004). The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU Int, 94(4), 603-605. doi:10.1111/j.1464-410X.2004.05009.x

Barroso-Sousa, R., da Fonseca, L. G., Souza, K. T., Chaves, A. C., Kann, A. G., de Castro, G., Jr., & Dzik, C. (2015). Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Med Oncol, 32(1), 443. doi:10.1007/s12032-014-0443-4

Bauer, R. M., Gozzi, C., Hubner, W., Nitti, V. W., Novara, G., Peterson, A., . . . Stief, C. G. (2011). Contemporary management of postprostatectomy incontinence. Eur Urol, 59(6), 985-996. doi:10.1016/j.eururo.2011.03.020

Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., . . . Gerritsen, W. (2017). Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol, 35(1), 40-47. doi:10.1200/jco.2016.69.1584

Beer, T. M., & Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med, 371(18), 1755-1756. doi:10.1056/NEJMc1410239

Bell, K. J., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer, 137(7), 1749-1757. doi:10.1002/ijc.29538

Berthold, D. R., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M., Tannock, A. I., & investigators, T. A. X. (2008). Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res, 14(9), 2763-2767. doi:10.1158/1078-0432.CCR-07-0944

Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 26(2), 242-245. doi:10.1200/JCO.2007.12.4008

Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., . . . Yialamas, M. A. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 103(5), 1715-1744. doi:10.1210/jc.2018-00229

Bienz, M., & Saad, F. (2015). Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. Bonekey Rep, 4, 716. doi:10.1038/bonekey.2015.85

Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., . . . Johansson, J. E. (2014). Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med, 370(10), 932-942. doi:10.1056/NEJMoa1311593

Boesen, L., Norgaard, N., Logager, V., Balslev, I., Bisbjerg, R., Thestrup, K. C., . . . Thomsen, H. S. (2019). Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naive Men. Eur Urol Oncol, 2(3), 311-319. doi:10.1016/j.euo.2018.09.001

Boesen, L., Nørgaard, N., Løgager, V., Balslev, I., Bisbjerg, R., Thestrup, K.-C., . . . Thomsen, H. (2018). Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men. The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open, June 2018.

Boeve, L. M. S., Hulshof, M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J., . . . van Andel, G. (2019). Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol, 75(3), 410-418. doi:10.1016/j.eururo.2018.09.008

Bolla, M., van Poppel, H., Collette, L., van Cangh, P., Vekemans, K., Da Pozzo, L., . . . Treatment of, C. (2005). Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 366(9485), 572-578. doi:10.1016/S0140-6736(05)67101-2

Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., . . . Genito-Urinary, G. (2012). Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 380(9858), 2018-2027. doi:10.1016/S0140-6736(12)61253-7

Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., . . . Collette, L. (2010). External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol, 11(11), 1066-1073. doi:10.1016/S1470-2045(10)70223-0

Bonn, S. E., Sjolander, A., Lagerros, Y. T., Wiklund, F., Stattin, P., Holmberg, E., . . . Balter, K. (2015). Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev, 24(1), 57-64. doi:10.1158/1055-9965.EPI-14-0707

Botrel, T. E., Clark, O., dos Reis, R. B., Pompeo, A. C., Ferreira, U., Sadi, M. V., & Bretas, F. F. (2014). Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol, 14, 9. doi:10.1186/1471-2490-14-9

Boudadi, K., & Antonarakis, E. S. (2016). Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol, 10(Suppl 1), 1-9. doi:10.4137/CMO.S34534

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Bratt, O., Damber, J. E., Emanuelsson, M., Kristoffersson, U., Lundgren, R., Olsson, H., & Gronberg, H. (2000). Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer, 36(2), 235-241. doi:10.1016/s0959-8049(99)00272-5

Bratt, O., Drevin, L., Akre, O., Garmo, H., & Stattin, P. (2016). Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. J Natl Cancer Inst, 108(10). doi:10.1093/jnci/djw110

Bratt, O., Folkvaljon, Y., Loeb, S., Klotz, L., Egevad, L., & Stattin, P. (2015). Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int, 116(2), 213-219. doi:10.1111/bju.12874

Bratt, O., Holmberg, E., Andren, O., Carlsson, S., Drevin, L., Johansson, E., . . . Robinsson, D. (2019). The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol, 76(4), 461-466. doi:10.1016/j.eururo.2019.02.035

Briganti, A., Karnes, J. R., Da Pozzo, L. F., Cozzarini, C., Gallina, A., Suardi, N., . . . Blute, M. L. (2009). Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol, 55(2), 261-270. doi:10.1016/j.eururo.2008.09.043

Briganti, A., Karnes, R. J., Joniau, S., Boorjian, S. A., Cozzarini, C., Gandaglia, G., . . . Wiegel, T. (2014). Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol, 66(3), 479-486. doi:10.1016/j.eururo.2013.11.045

Briganti, A., Wiegel, T., Joniau, S., Cozzarini, C., Bianchi, M., Sun, M., . . . Van Poppel, H. (2012). Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol, 62(3), 472-487. doi:10.1016/j.eururo.2012.04.056

Budaus, L., Bolla, M., Bossi, A., Cozzarini, C., Crook, J., Widmark, A., & Wiegel, T. (2012). Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol, 61(1), 112-127. doi:10.1016/j.eururo.2011.09.027

Burdett, S., Boeve, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., . . . Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol, 76(1), 115-124. doi:10.1016/j.eururo.2019.02.003

Burri, R. J., Stone, N. N., Unger, P., & Stock, R. G. (2010). Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 77(5), 1338-1344. doi:10.1016/j.ijrobp.2009.06.061

Busch, J., Hamborg, K., Meyer, H. A., Buckendahl, J., Magheli, A., Lein, M., . . . Stephan, C. (2012). Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis. J Urol, 188(6), 2165-2170. doi:10.1016/j.juro.2012.07.106

Calais, J., Fendler, W. P., Eiber, M., Gartmann, J., Chu, F. I., Nickols, N. G., . . . Herrmann, K. (2018). Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med, 59(3), 434-441. doi:10.2967/jnumed.117.202945

Cameron, M. G., Kersten, C., Guren, M. G., Fossa, S. D., & Vistad, I. (2014). Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review. Radiother Oncol, 110(1), 55-60. doi:10.1016/j.radonc.2013.08.008

Campbell, S. E., Glazener, C. M., Hunter, K. F., Cody, J. D., & Moore, K. N. (2012). Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev, 1, CD001843. doi:10.1002/14651858.CD001843.pub4

Cao, D., Humphrey, P. A., Gao, F., Tao, Y., & Kibel, A. S. (2011). Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology, 77(6), 1409-1414. doi:10.1016/j.urology.2010.10.059

Carlsson, S., Assel, M., Sjoberg, D., Ulmert, D., Hugosson, J., Lilja, H., & Vickers, A. (2014). Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ, 348, g2296. doi:10.1136/bmj.g2296

Carlsson, S., Benfante, N., Alvim, R., Sjoberg, D. D., Vickers, A., Reuter, V. E., . . . Touijer, K. (2019). Long-Term Outcomes of Active Surveillance for Prostate Cancer - The Memorial Sloan Kettering Cancer Center Experience. J Urol, 101097ju0000000000000713. doi:10.1097/ju.0000000000000713

Carlsson, S., Berglund, A., Sjoberg, D., Khatami, A., Stranne, J., Bergdahl, S., . . . Hugosson, J. (2014). Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol, 14, 25. doi:10.1186/1471-2490-14-25

Carlsson, S., Nilsson, A. E., Schumacher, M. C., Jonsson, M. N., Volz, D. S., Steineck, G., & Wiklund, P. N. (2010). Surgery-related complications in 1253 robot-assisted and 485 open retropubic radical prostatectomies at the Karolinska University Hospital, Sweden. Urology, 75(5), 1092-1097. doi:10.1016/j.urology.2009.09.075

Carrie, C., Magne, N., Burban-Provost, P., Sargos, P., Latorzeff, I., Lagrange, J. L., . . . Chabaud, S. (2019). Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. doi:10.1016/s1470-2045(19)30486-3

Casey, R. G., Hegarty, P. K., Conroy, R., Rea, D., Butler, M. R., Grainger, R., . . . Thornhill, J. A. (2012). The Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70. ISRN Oncol, 2012, 832109. doi:10.5402/2012/832109

Cash, H., Gunzel, K., Maxeiner, A., Stephan, C., Fischer, T., Durmus, T., . . . Kempkensteffen, C. (2016). Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int, 118(1), 35-43. doi:10.1111/bju.13327

Castle, K. O., Hoffman, K. E., Levy, L. B., Lee, A. K., Choi, S., Nguyen, Q. N., . . . Kuban, D. A. (2013). Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys, 85(3), 693-699. doi:10.1016/j.ijrobp.2012.06.030

Catton, C. N., Lukka, H., Gu, C. S., Martin, J. M., Supiot, S., Chung, P. W. M., . . . Levine, M. N. (2017). Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol, 35(17), 1884-1890. doi:10.1200/JCO.2016.71.7397

Chade, D. C., Eastham, J., Graefen, M., Hu, J. C., Karnes, R. J., Klotz, L., . . . Shariat, S. F. (2012). Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol, 61(5), 961-971. doi:10.1016/j.eururo.2012.01.022

Chen, C. P., Weinberg, V., Shinohara, K., Roach, M., 3rd, Nash, M., Gottschalk, A., . . . Hsu, I. C. (2013). Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys, 86(2), 324-329. doi:10.1016/j.ijrobp.2013.01.027

Choe, K. S., Jani, A. B., & Liauw, S. L. (2010). External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys, 76(3), 755-760. doi:10.1016/j.ijrobp.2009.02.026

Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol), 24(2), 112-124. doi:10.1016/j.clon.2011.11.004

Chung, E., & Brock, G. (2013). Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med, 10 Suppl 1, 102-111. doi:10.1111/j.1743-6109.2012.03005.x

Cooper, C. S., Eeles, R., Wedge, D. C., Van Loo, P., Gundem, G., Alexandrov, L. B., . . . Neal, D. E. (2015). Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet, 47(4), 367-372. doi:10.1038/ng.3221

Cornu, J. N., Merlet, B., Ciofu, C., Mouly, S., Peyrat, L., Sebe, P., . . . Haab, F. (2011). Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol, 59(1), 148-154. doi:10.1016/j.eururo.2010.10.031

Crawford, E. D., Shore, N. D., Moul, J. W., Tombal, B., Schroder, F. H., Miller, K., . . . Klotz, L. (2014). Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology, 83(5), 1122-1128. doi:10.1016/j.urology.2014.01.013

Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., . . . Umar, A. (2015). Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol, 26(1), 47-57. doi:10.1093/annonc/mdu225

D'Amico, A. V., Chen, M. H., Catalona, W. J., Sun, L., Roehl, K. A., & Moul, J. W. (2007). Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer, 110(1), 56-61. doi:10.1002/cncr.22737

D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, B., & Kantoff, P. W. (2008a). Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol, 26(18), 2979-2983. doi:10.1200/JCO.2007.15.9699

D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008b). Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama, 299(3), 289-295. doi:10.1001/jama.299.3.289

D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Fondurulia, J., Chen, M. H., . . . Richie, J. P. (2000). Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol, 18(6), 1164-1172.

Danneman, D., Wiklund, F., Wiklund, N. P., & Egevad, L. (2013). Prognostic significance of histopathological features of extraprostatic extension of prostate cancer. Histopathology, 63(4), 580-589. doi:10.1111/his.12199

Dayes, I. S., Parpia, S., Gilbert, J., Julian, J. A., Davis, I. R., Levine, M. N., & Sathya, J. (2017). Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Int J Radiat Oncol Biol Phys, 99(1), 90-93. doi:10.1016/j.ijrobp.2017.05.013

de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., . . . Investigators, T. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376(9747), 1147-1154. doi:10.1016/S0140-6736(10)61389-X

De Santis, M., & Saad, F. (2016). Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer. Urology, 96, 156-164. doi:10.1016/j.urology.2016.02.010

Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., . . . Investigators, C. H. (2016). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol, 17(8), 1047-1060. doi:10.1016/S1470-2045(16)30102-4

Delahunt, B., Egevad, L., Srigley, J. R., Steigler, A., Murray, J. D., Atkinson, C., . . . Denham, J. W. (2015). Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data. Pathology, 47(6), 520-525. doi:10.1097/PAT.0000000000000318

Demanes, D. J., & Ghilezan, M. I. (2014). High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy, 13(6), 529-541. doi:10.1016/j.brachy.2014.03.002

Demanes, D. J., Martinez, A. A., Ghilezan, M., Hill, D. R., Schour, L., Brandt, D., & Gustafson, G. (2011). High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys, 81(5), 1286-1292. doi:10.1016/j.ijrobp.2010.10.015

Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Turner, S., Matthews, J., . . . D'Este, C. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol, 12(5), 451-459. doi:10.1016/S1470-2045(11)70063-8

Dieperink, K. B., Johansen, C., Hansen, S., Wagner, L., Andersen, K. K., Minet, L. R., & Hansen, O. (2013). The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. Br J Cancer, 109(12), 3005-3013. doi:10.1038/bjc.2013.679

Din skyldighet att informera. Socialstyrelsen 2015.

Dirix, P., Joniau, S., Van den Bergh, L., Isebaert, S., Oyen, R., Deroose, C. M., . . . Haustermans, K. (2014). The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: a systematic review. Radiother Oncol, 110(1), 45-54. doi:10.1016/j.radonc.2013.06.046

Distler, F. A., Radtke, J. P., Bonekamp, D., Kesch, C., Schlemmer, H. P., Wieczorek, K., . . . Hadaschik, B. A. (2017). The Value of PSA Density in Combination with PI-RADS for the Accuracy of Prostate Cancer Prediction. J Urol, 198(3), 575-582. doi:10.1016/j.juro.2017.03.130

Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A., Schroder, F. H., & de Koning, H. J. (2003). Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 95(12), 868-878.

Drost, F. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019). Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev, 4, Cd012663. doi:10.1002/14651858.CD012663.pub2

Duijzentkunst, D. A., Peters, M., van der Voort van Zyp, J. R., Moerland, M. A., & van Vulpen, M. (2016). Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol, 34(11), 1521-1531. doi:10.1007/s00345-016-1811-9

Eeles, R., Goh, C., Castro, E., Bancroft, E., Guy, M., Al Olama, A. A., . . . Kote-Jarai, Z. (2014). The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol, 11(1), 18-31. doi:10.1038/nrurol.2013.266

Egevad, L., Ahmad, A. S., Algaba, F., Berney, D. M., Boccon-Gibod, L., Comperat, E., . . . Camparo, P. (2013). Standardization of Gleason grading among 337 European pathologists. Histopathology, 62(2), 247-256. doi:10.1111/his.12008

Egevad, L., Algaba, F., Berney, D. M., Boccon-Gibod, L., Griffiths, D. F., Lopez-Beltran, A., . . . European Network of, U. (2008). Handling and reporting of radical prostatectomy specimens in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology, 53(3), 333-339. doi:10.1111/j.1365-2559.2008.03102.x

Egevad, L., Granfors, T., Karlberg, L., Bergh, A., & Stattin, P. (2002). Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol, 168(2), 509-513.

Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Geczi, L., Ford, D., Mourey, L., . . . de Bono, J. (2017). Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol, 35(28), 3198-3206. doi:10.1200/JCO.2016.72.1076

Elliott, J., Kelly, S. E., Millar, A. C., Peterson, J., Chen, L., Johnston, A., . . . Wells, G. A. (2017). Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open, 7(11), e015284. doi:10.1136/bmjopen-2016-015284

Ellis, C. L., Walsh, P. C., Partin, A. W., & Epstein, J. I. (2013). Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU Int, 111(8), E306-309. doi:10.1111/j.1464-410X.2012.11680.x

Engel, J., Bastian, P. J., Baur, H., Beer, V., Chaussy, C., Gschwend, J. E., . . . Holzel, D. (2010). Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol, 57(5), 754-761. doi:10.1016/j.eururo.2009.12.034

Engholm, G., Ferlay, J., Christensen, N., Bray, F., Gjerstorff, M. L., Klint, A., . . . Storm, H. H. (2010). NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol, 49(5), 725-736. doi:10.3109/02841861003782017

Engholm, G., Ferlay, J., Christensen, N., Kejs, A. M. T., Johannesen, T. B., Khan, S., . . . Storm, H. H. (2015, 16.12.2015). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.2 (16.12.2015). Association of the Nordic Cancer Registries.

Epstein, J. I., Allsbrook, W. C., Jr., Amin, M. B., Egevad, L. L., & Committee, I. G. (2005). The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 29(9), 1228-1242.

Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., Humphrey, P. A., & Grading, C. (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol, 40(2), 244-252. doi:10.1097/PAS.0000000000000530

Epstein, J. I., Egevad, L., Humphrey, P. A., Montironi, R., & Members of the, I. I. i. D. U. P. G. (2014). Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol, 38(8), e6-e19. doi:10.1097/PAS.0000000000000238

European Partnership Action Against Cancer consensus, g., Borras, J. M., Albreht, T., Audisio, R., Briers, E., Casali, P., . . . Wilson, R. (2014). Policy statement on multidisciplinary cancer care. Eur J Cancer, 50(3), 475-480. doi:10.1016/j.ejca.2013.11.012

Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., . . . Hadaschik, B. (2019). Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. doi:10.1158/1078-0432.Ccr-19-1050

Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., . . . Mottrie, A. (2012). Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol, 62(3), 405-417. doi:10.1016/j.eururo.2012.05.045

Fine, S. W. (2012). Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations. Adv Anat Pathol, 19(4), 204-216. doi:10.1097/PAP.0b013e31825c6b92

Finney, G., Haynes, A. M., Cross, P., Brenner, P., Boyn, A., & Stricker, P. (2005). Cross-sectional analysis of sexual function after prostate brachytherapy. Urology, 66(2), 377-381. doi:10.1016/j.urology.2005.03.045

Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., . . . Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813-822. doi:10.1016/S0140-6736(10)62344-6

Fizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., . . . Culine, S. (2015). Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol, 16(7), 787-794. doi:10.1016/S1470-2045(15)00011-X

Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., . . . Investigators, C.-A.-. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13(10), 983-992. doi:10.1016/S1470-2045(12)70379-0

Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., . . . Smith, M. R. (2019). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med, 380(13), 1235-1246. doi:10.1056/NEJMoa1815671

Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., . . . Chi, K. N. (2017). Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 377(4), 352-360. doi:10.1056/NEJMoa1704174

Fleshner, N. E., Lucia, M. S., Egerdie, B., Aaron, L., Eure, G., Nandy, I., . . . Rittmaster, R. S. (2012). Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet, 379(9821), 1103-1111. doi:10.1016/S0140-6736(11)61619-X

Fode, M., & Sonksen, J. (2014). Sexual Function in Elderly Men Receiving Androgen Deprivation Therapy (ADT). Sex Med Rev, 2(1), 36-46. doi:10.1002/smrj.17

Foerster, B., Pozo, C., Abufaraj, M., Mari, A., Kimura, S., D'Andrea, D., . . . Shariat, S. F. (2018). Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. JAMA Oncol, 4(7), 953-961. doi:10.1001/jamaoncol.2018.1071

Fossa, S. D., Jacobsen, A. B., Ginman, C., Jacobsen, I. N., Overn, S., Iversen, J. R., . . . Sandstad, B. (2007). Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol, 52(6), 1691-1698. doi:10.1016/j.eururo.2007.01.104

Fossati, N., Willemse, P. M., Van den Broeck, T., van den Bergh, R. C. N., Yuan, C. Y., Briers, E., . . . Joniau, S. (2017). The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol, 72(1), 84-109. doi:10.1016/j.eururo.2016.12.003

Fradet, Y., Egerdie, B., Andersen, M., Tammela, T. L., Nachabe, M., Armstrong, J., . . . Navani, S. (2007). Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol, 52(1), 106-114. doi:10.1016/j.eururo.2007.01.031

Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005). Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama, 294(4), 433-439. doi:10.1001/jama.294.4.433

Friethriksson, J. O., Holmberg, E., Adolfsson, J., Lambe, M., Bill-Axelson, A., Carlsson, S., . . . Stattin, P. (2014). Rehospitalization after radical prostatectomy in a nationwide, population based study. J Urol, 192(1), 112-119. doi:10.1016/j.juro.2014.01.109

Galalae, R. M., Zakikhany, N. H., Geiger, F., Siebert, F. A., Bockelmann, G., Schultze, J., & Kimmig, B. (2014). The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone? Brachytherapy, 13(2), 117-122. doi:10.1016/j.brachy.2013.11.002

Gandaglia, G., Sammon, J. D., Chang, S. L., Choueiri, T. K., Hu, J. C., Karakiewicz, P. I., . . . Trinh, Q. D. (2014). Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol, 32(14), 1419-1426. doi:10.1200/JCO.2013.53.5096

Garcia-Reyes, K., Passoni, N. M., Palmeri, M. L., Kauffman, C. R., Choudhury, K. R., Polascik, T. J., & Gupta, R. T. (2015). Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging, 40(1), 134-142. doi:10.1007/s00261-014-0197-7

Gardner, J. R., Livingston, P. M., & Fraser, S. F. (2014). Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol, 32(4), 335-346. doi:10.1200/JCO.2013.49.5523

Garnick, M. B., & Mottet, N. (2012). New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int, 110(4), 499-504. doi:10.1111/j.1464-410X.2011.10708.x

Gaziev, G., Wadhwa, K., Barrett, T., Koo, B. C., Gallagher, F. A., Serrao, E., . . . Kastner, C. (2014). Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int. doi:10.1111/bju.12892

Gaziev, G., Wadhwa, K., Barrett, T., Koo, B. C., Gallagher, F. A., Serrao, E., . . . Kastner, C. (2016). Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int, 117(1), 80-86. doi:10.1111/bju.12892

Geerkens, M. J. M., Pouwels, N. S. A., & Beerlage, H. P. (2019). The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review. Qual Life Res. doi:10.1007/s11136-019-02361-z

Geraerts, I., Van Poppel, H., Devoogdt, N., Laenen, A., De Groef, A., & Van Kampen, M. (2014). Progression and predictors of physical activity levels after radical prostatectomy. BJU Int, 114(2), 185-192. doi:10.1111/bju.12465

Ghilezan, M., Martinez, A., Gustason, G., Krauss, D., Antonucci, J. V., Chen, P., . . . Limbacher, A. (2012). High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys, 83(3), 927-932. doi:10.1016/j.ijrobp.2011.05.001

Ghosh, P. (2014). The role of SPECT/CT in skeletal malignancies. Semin Musculoskelet Radiol, 18(2), 175-193. doi:10.1055/s-0034-1371019

Gilbert, D. C., Duong, T., Kynaston, H. G., Alhasso, A. A., Cafferty, F. H., Rosen, S. D., . . . Abel, P. D. (2017). Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int, 119(5), 667-675. doi:10.1111/bju.13687

Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., . . . Tombal, B. (2015). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol, 26(8), 1589-1604. doi:10.1093/annonc/mdv257

Glass, A. S., & Dall'Era, M. A. (2019). Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU Int, 124(5), 730-737. doi:10.1111/bju.14705

Gogna, N. K., Baxi, S., Hickey, B., Baumann, K., Burmeister, E., & Holt, T. (2012). Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer. Int J Radiat Oncol Biol Phys, 83(2), e205-211. doi:10.1016/j.ijrobp.2011.12.028

Goldberg, H., Ahmad, A. E., Chandrasekar, T., Klotz, L., Emberton, M., Haider, M. A., . . . Wallis, C. J. D. (2019). Comparison of MRI- and TRUS-Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy-Naive Men: A Systematic Review and Meta-Analysis. J Urol, 101097ju0000000000000595. doi:10.1097/ju.0000000000000595

Golla, V., & Kaplan, A. L. (2017). Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer. Curr Urol Rep, 18(7), 49. doi:10.1007/s11934-017-0695-6

Gortz, M., Radtke, J. P., Hatiboglu, G., Schutz, V., Tosev, G., Guttlein, M., . . . Nyarangi-Dix, J. N. (2019). The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. Eur Urol Focus. doi:10.1016/j.euf.2019.11.012

Grant, K. B., Agarwal, H. K., Shih, J. H., Bernardo, M., Pang, Y., Daar, D., . . . Turkbey, B. (2015). Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer. Abdom Imaging, 40(3), 578-586. doi:10.1007/s00261-014-0246-2

Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., . . . Soulie, M. (2013). Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 14(2), 149-158. doi:10.1016/S1470-2045(12)70560-0

Gronberg, H., Adolfsson, J., Aly, M., Nordstrom, T., Wiklund, P., Brandberg, Y., . . . Eklund, M. (2015). Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol, 16(16), 1667-1676. doi:10.1016/S1470-2045(15)00361-7

Gronberg, H., Eklund, M., Lindberg, J., Ullén, A., Bjartell, A., Andren, O., . . . Thellenberg, C. (2018). ProBio II: An adaptive and randomized multi-arm biomarker driven phase 2 study in men with castrate resistant prostate cancer (CRPC). Journal of Clinical Oncology, 36(6_suppl), TPS397-TPS397. doi:10.1200/JCO.2018.36.6_suppl.TPS397

Gronberg, H., Eklund, M., Picker, W., Aly, M., Jaderling, F., Adolfsson, J., . . . Nordstrom, T. (2018). Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol, 74(6), 722-728. doi:10.1016/j.eururo.2018.06.022

Gronberg, H., Wiklund, F., & Damber, J. E. (1999). Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer, 86(3), 477-483.

Groves, A. M., Beadsmoore, C. J., Cheow, H. K., Balan, K. K., Courtney, H. M., Kaptoge, S., . . . Dixon, A. K. (2006). Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient. Eur Radiol, 16(5), 1066-1073. doi:10.1007/s00330-005-0042-z

Grubmuller, B., Baltzer, P., D'Andrea, D., Korn, S., Haug, A. R., Hacker, M., . . . Hartenbach, M. (2018). (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging, 45(2), 235-242. doi:10.1007/s00259-017-3858-2

Grummet, J. P., Weerakoon, M., Huang, S., Lawrentschuk, N., Frydenberg, M., Moon, D. A., . . . Murphy, D. (2014). Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int, 114(3), 384-388. doi:10.1111/bju.12536

Guillaumier, S., Peters, M., Arya, M., Afzal, N., Charman, S., Dudderidge, T., . . . Ahmed, H. U. (2018). A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol, 74(4), 422-429. doi:10.1016/j.eururo.2018.06.006

Haggstrom, C., Stocks, T., Ulmert, D., Bjorge, T., Ulmer, H., Hallmans, G., . . . Stattin, P. (2012). Prospective study on metabolic factors and risk of prostate cancer. Cancer, 118(24), 6199-6206. doi:10.1002/cncr.27677

Haglind, E., Carlsson, S., Stranne, J., Wallerstedt, A., Wilderang, U., Thorsteinsdottir, T., . . . committee, L. s. (2015). Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. Eur Urol, 68(2), 216-225. doi:10.1016/j.eururo.2015.02.029

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., . . . Small, E. J. (2016). Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol, 34(14), 1652-1659. doi:10.1200/JCO.2015.65.7270

Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., . . . Protec, T. S. G. (2016). 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med, 375(15), 1415-1424. doi:10.1056/NEJMoa1606220

Hamdy, F. C., & Williams, J. L. (1995). Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol, 75(6), 782-785.

Hansen, N. L., Barrett, T., Koo, B., Doble, A., Gnanapragasam, V., Warren, A., . . . Bratt, O. (2017). The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. BJU Int, 119(5), 724-730. doi:10.1111/bju.13619

Hanson, B., MacDonald, R., & Shaukat, A. (2012). Endoscopic and medical therapy for chronic radiation proctopathy: a systematic review. Dis Colon Rectum, 55(10), 1081-1095. doi:10.1097/DCR.0b013e3182587aef

Harrington, C., Campbell, G., Wynne, C., & Atkinson, C. (2010). Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol, 54(3), 224-228. doi:10.1111/j.1754-9485.2010.02168.x

Hauswald, H., Kamrava, M. R., Fallon, J. M., Wang, P. C., Park, S. J., Van, T., . . . Demanes, D. J. (2016). High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. Int J Radiat Oncol Biol Phys, 94(4), 667-674. doi:10.1016/j.ijrobp.2015.07.2290

Heck, M. M., Tauber, R., Schwaiger, S., Retz, M., D’Alessandria, C., Maurer, T., . . . Eiber, M. (2019). Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. European Urology, 75(6), 920-926. doi:https://doi.org/10.1016/j.eururo.2018.11.016

Hedlund, P. O., Damber, J. E., Hagerman, I., Haukaas, S., Henriksson, P., Iversen, P., . . . Group, S.-S. (2008). Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol, 42(3), 220-229. doi:10.1080/00365590801943274

Hedlund, P. O., Johansson, R., Damber, J. E., Hagerman, I., Henriksson, P., Iversen, P., . . . Spcg-5 Study, G. (2011). Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol, 45(5), 346-353. doi:10.3109/00365599.2011.585820

Hickey, B. E., James, M. L., Daly, T., Soh, F. Y., & Jeffery, M. (2019). Hypofractionation for clinically localized prostate cancer. Cochrane Database of Systematic Reviews(9). doi:10.1002/14651858.CD011462.pub2

Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., . . . Shapiro, C. L. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. Jama, 317(1), 48-58. doi:10.1001/jama.2016.19425

Ho, T., Howard, L. E., Vidal, A. C., Gerber, L., Moreira, D., McKeever, M., . . . Freedland, S. J. (2014). Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clin Cancer Res, 20(20), 5331-5338. doi:10.1158/1078-0432.CCR-13-2394

Hoffman, R. M., Koyama, T., Fan, K. H., Albertsen, P. C., Barry, M. J., Goodman, M., . . . Penson, D. F. (2013). Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst, 105(10), 711-718. doi:10.1093/jnci/djt059

Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., . . . Sandhu, S. (2018). [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol, 19(6), 825-833. doi:10.1016/s1470-2045(18)30198-0

Hong, S. K., Na, W., Park, J. M., Byun, S. S., Oh, J. J., Nam, J. S., . . . Lee, S. E. (2011). Prediction of pathological outcomes for a single microfocal (</=3 mm) Gleason 6 prostate cancer detected via contemporary multicore (>/=12) biopsy in men with prostate-specific antigen </=10 ng/mL. BJU Int, 108(7), 1101-1105. doi:10.1111/j.1464-410X.2010.09996.x

Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., . . . Shipley, W. U. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol, 26(15), 2497-2504. doi:10.1200/JCO.2007.14.9021

Hoskin, P. J., Rojas, A. M., Bownes, P. J., Lowe, G. J., Ostler, P. J., & Bryant, L. (2012). Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol, 103(2), 217-222. doi:10.1016/j.radonc.2012.01.007

Hovels, A. M., Heesakkers, R. A., Adang, E. M., Jager, G. J., Strum, S., Hoogeveen, Y. L., . . . Barentsz, J. O. (2008). The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol, 63(4), 387-395. doi:10.1016/j.crad.2007.05.022

Huang, E. H., Pollack, A., Levy, L., Starkschall, G., Dong, L., Rosen, I., & Kuban, D. A. (2002). Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 54(5), 1314-1321.

Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., . . . Lilja, H. (2010). Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol, 11(8), 725-732. doi:10.1016/S1470-2045(10)70146-7

Huisman, M., van den Bosch, M. A., Wijlemans, J. W., van Vulpen, M., van der Linden, Y. M., & Verkooijen, H. M. (2012). Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys, 84(1), 8-14. doi:10.1016/j.ijrobp.2011.10.080

Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., . . . Sternberg, C. N. (2018). Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med, 378(26), 2465-2474. doi:10.1056/NEJMoa1800536

Ilic, D., Hindson, B., Duchesne, G., & Millar, J. L. (2013). A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol, 57(1), 81-88. doi:10.1111/j.1754-9485.2012.02461.x

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. (1997). Br J Urol, 79(2), 235-246.

Incrocci, L., & Jensen, P. T. (2013). Pelvic radiotherapy and sexual function in men and women. J Sex Med, 10 Suppl 1, 53-64. doi:10.1111/jsm.12010

Incrocci, L., Wortel, R. C., Alemayehu, W. G., Aluwini, S., Schimmel, E., Krol, S., . . . Pos, F. (2016). Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 17(8), 1061-1069. doi:10.1016/S1470-2045(16)30070-5

Islami, F., Moreira, D. M., Boffetta, P., & Freedland, S. J. (2014). A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol, 66(6), 1054-1064. doi:10.1016/j.eururo.2014.08.059

Ito, K., Yamamoto, T., Kubota, Y., Suzuki, K., Fukabori, Y., Kurokawa, K., & Yamanaka, H. (2000). Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology, 56(2), 278-282.

Iu, P. P. (2013). ESUR prostate MR guidelines. Eur Radiol, 23(8), 2320-2321. doi:10.1007/s00330-013-2892-0

Iversen, P., Johansson, J. E., Lodding, P., Kylmala, T., Lundmo, P., Klarskov, P., . . . Scandinavian Prostate Cancer, G. (2006). Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol, 40(6), 441-452. doi:10.1080/00365590601017329

Iversen, P., McLeod, D. G., See, W. A., Morris, T., Armstrong, J., Wirth, M. P., & Casodex Early Prostate Cancer Trialists, G. (2010). Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int, 105(8), 1074-1081. doi:10.1111/j.1464-410X.2010.09319.x

Iversen, P., Tveter, K., & Varenhorst, E. (1996). Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol, 30(2), 93-98.

Jagervall, C., Gunnarsson, A. B., & Bruggemann, A. (2016). [Not Available]. Lakartidningen, 113.

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., . . . Sydes, M. R. (2017). Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med, 377(4), 338-351. doi:10.1056/NEJMoa1702900

James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., . . . Sydes, M. R. (2015). Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol, 67(6), 1028-1038. doi:10.1016/j.eururo.2014.09.032

James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., . . . Investigators, S. (2015). Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol, 1-10. doi:10.1001/jamaoncol.2015.4350

James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., . . . investigators, S. (2015). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. doi:10.1016/S0140-6736(15)01037-5

Jellvert, A., Lissbrant, I. F., Edgren, M., Ovferholm, E., Braide, K., Olvenmark, A. M., . . . Lennernas, B. (2011). Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med, 2(4), 579-584. doi:10.3892/etm.2011.272

Jin, T., Song, T., Deng, S., & Wang, K. (2014). Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. Urol Int, 93(3), 279-288. doi:10.1159/000356115

Johansson, J. E., Andersson, S. O., & Holmberg, L. (1991). High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol, 68(1), 67-73.

Jolnerovski, M., Salleron, J., Beckendorf, V., Peiffert, D., Baumann, A. S., Bernier, V., . . . Chira, C. (2017). Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Radiat Oncol, 12(1), 99. doi:10.1186/s13014-017-0839-3

Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., . . . Shipley, W. U. (2011). Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med, 365(2), 107-118. doi:10.1056/NEJMoa1012348

Kadono, Y., Machioka, K., Nakashima, K., Iijima, M., Shigehara, K., Nohara, T., . . . Mizokami, A. (2017). Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism. BJU Int, 120(2), 293-299. doi:10.1111/bju.13777

Kalkner, K. M., Wahlgren, T., Ryberg, M., Cohn-Cedermark, G., Castellanos, E., Zimmerman, R., . . . Nilsson, S. (2007). Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol, 46(7), 909-917. doi:10.1080/02841860601156140

Kamada, S., Sakamoto, S., Ando, K., Muroi, A., Fuse, M., Kawamura, K., . . . Ichikawa, T. (2015). Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. J Urol, 194(5), 1264-1270. doi:10.1016/j.juro.2015.03.120

Karantanos, T., Evans, C. P., Tombal, B., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2015). Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol, 67(3), 470-479. doi:10.1016/j.eururo.2014.09.049

Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., . . . Wiklund, F. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol, 65(1), 169-176. doi:10.1016/j.eururo.2012.07.027

Karsh, L. I., Gross, E. T., Pieczonka, C. M., Aliotta, P. J., Skomra, C. J., Ponsky, L. E., . . . Shore, N. D. (2018). Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology, 115, 39-44. doi:10.1016/j.urology.2017.11.016

Kawakami, S., Yamamoto, S., Numao, N., Ishikawa, Y., Kihara, K., & Fukui, I. (2007). Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol, 14(8), 719-724. doi:10.1111/j.1442-2042.2007.01810.x

Kellokumpu-Lehtinen, P. L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., . . . group, P. s. (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol, 14(2), 117-124. doi:10.1016/S1470-2045(12)70537-5

Kellokumpu-Lehtinen, P. L., Hjalm-Eriksson, M., Thellenberg-Karlsson, C., Astrom, L., Franzen, L., Fransson, A. S., . . . Ginman, C. (2019). Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. Eur Urol. doi:10.1016/j.eururo.2019.08.010

Kenfield, S. A., Stampfer, M. J., Chan, J. M., & Giovannucci, E. (2011). Smoking and prostate cancer survival and recurrence. Jama, 305(24), 2548-2555. doi:10.1001/jama.2011.879

Keulers, B. J., Scheltinga, M. R., Houterman, S., Van Der Wilt, G. J., & Spauwen, P. H. (2008). Surgeons underestimate their patients' desire for preoperative information. World J Surg, 32(6), 964-970. doi:10.1007/s00268-008-9581-1

Kicinski, M., Vangronsveld, J., & Nawrot, T. S. (2011). An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One, 6(10), e27130. doi:10.1371/journal.pone.0027130

Kim, M. M., Hoffman, K. E., Levy, L. B., Frank, S. J., Pugh, T. J., Choi, S., . . . Kuban, D. A. (2012). Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer, 48(11), 1664-1671. doi:10.1016/j.ejca.2012.01.026

King, C. R. (2012). The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys, 84(1), 104-111. doi:10.1016/j.ijrobp.2011.10.069

Kishan, A. U., Cook, R. R., Ciezki, J. P., Ross, A. E., Pomerantz, M. M., Nguyen, P. L., . . . King, C. R. (2018). Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama, 319(9), 896-905. doi:10.1001/jama.2018.0587

Kjolhede, H., Ahlgren, G., Almquist, H., Liedberg, F., Lyttkens, K., Ohlsson, T., & Bratt, O. (2012). Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int, 110(10), 1501-1506. doi:10.1111/j.1464-410X.2012.11123.x

Klein, E. A., Thompson, I. M., Jr., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., . . . Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama, 306(14), 1549-1556. doi:10.1001/jama.2011.1437

Klotz, L. (2013). Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol, 14(1), 97-108. doi:10.1007/s11864-012-0221-5

Klotz, L. (2019). Active surveillance in intermediate-risk prostate cancer. BJU Int. doi:10.1111/bju.14935

Klotz, L., O'Callaghan, C., Ding, K., Toren, P., Dearnaley, D., Higano, C. S., . . . Crook, J. M. (2015). Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol, 33(10), 1151-1156. doi:10.1200/JCO.2014.58.2973

Koulikov, D., Mohler, M. C., Mehedint, D. C., Attwood, K., Wilding, G. E., & Mohler, J. L. (2014). Low detectable prostate specific antigen after radical prostatectomy--treat or watch? J Urol, 192(5), 1390-1396. doi:10.1016/j.juro.2014.05.088

Kuban, D. (2012). Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer  RSS. Int J Rad Onc, 54(5).

Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M. D. (2006). Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev(4), CD006019. doi:10.1002/14651858.CD006019.pub2

Kweldam, C. F., Kummerlin, I. P., Nieboer, D., Verhoef, E. I., Steyerberg, E. W., van der Kwast, T. H., . . . van Leenders, G. J. (2016). Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol, 29(6), 630-636. doi:10.1038/modpathol.2016.49

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J., . . . Gerritsen, W. R. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 15(7), 700-712. doi:10.1016/s1470-2045(14)70189-5

Kvorning Ternov, K., Krag Jakobsen, A., Bratt, O., & Ahlgren, G. (2015). Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer. Scand J Urol, 49(2), 115-119. doi:10.3109/21681805.2014.968869

Langley, R. E., Cafferty, F. H., Alhasso, A. A., Rosen, S. D., Sundaram, S. K., Freeman, S. C., . . . Abel, P. D. (2013). Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol, 14(4), 306-316. doi:10.1016/S1470-2045(13)70025-1

Lebdai, S., Basset, V., Branchereau, J., de La Taille, A., Flamand, V., Lebret, T., . . . Audenet, F. (2016). What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World J Urol, 34(5), 617-624. doi:10.1007/s00345-015-1687-0

Lecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., . . . Ottini, L. (2017). Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol, 35(20), 2240-2250. doi:10.1200/JCO.2016.69.4935

Lecouvet, F. E., El Mouedden, J., Collette, L., Coche, E., Danse, E., Jamar, F., . . . Tombal, B. (2012). Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol, 62(1), 68-75. doi:10.1016/j.eururo.2012.02.020

Lee, B., Shinohara, K., Weinberg, V., Gottschalk, A. R., Pouliot, J., Roach, M., 3rd, & Hsu, I. C. (2007). Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys, 67(4), 1106-1112. doi:10.1016/j.ijrobp.2006.10.012

Lee, R., Localio, A. R., Armstrong, K., Malkowicz, S. B., Schwartz, J. S., & Free, P. S. A. S. G. (2006). A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology, 67(4), 762-768. doi:10.1016/j.urology.2005.10.052

Lee, W. R., Dignam, J. J., Amin, M. B., Bruner, D. W., Low, D., Swanson, G. P., . . . Sandler, H. M. (2016). Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol, 34(20), 2325-2332. doi:10.1200/JCO.2016.67.0448

Ligibel, J. (2012). Lifestyle factors in cancer survivorship. J Clin Oncol, 30(30), 3697-3704. doi:10.1200/JCO.2012.42.0638

Lilja, H., Cronin, A. M., Dahlin, A., Manjer, J., Nilsson, P. M., Eastham, J. A., . . . Vickers, A. J. (2011). Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer, 117(6), 1210-1219. doi:10.1002/cncr.25568

Lin, H., & Wang, R. (2013). The science of vacuum erectile device in penile rehabilitation after radical prostatectomy. Transl Androl Urol, 2(1), 61-66. doi:10.3978/j.issn.2223-4683.2013.01.04

Lithner, M., & Zilling, T. (1998). Does preoperative information increase the wellbeing of the patient after surgery? (Vol. 18): Vård i Norden.

Ljunggren, C., & Stroberg, P. (2015). Improvement in sexual function after robot-assisted radical prostatectomy: A rehabilitation program with involvement of a clinical sexologist. Cent European J Urol, 68(2), 214-220. doi:10.5173/ceju.2015.484

Loblaw, D. A., Mitera, G., Ford, M., & Laperriere, N. J. (2012). A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys, 84(2), 312-317. doi:10.1016/j.ijrobp.2012.01.014

Loeb, S., Folkvaljon, Y., Damber, J. E., Alukal, J., Lambe, M., & Stattin, P. (2017). Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. J Clin Oncol, 35(13), 1430-1436. doi:10.1200/JCO.2016.69.5304

Loeb, S., Folkvaljon, Y., Robinson, D., Lissbrant, I. F., Egevad, L., & Stattin, P. (2015). Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. Eur Urol. doi:10.1016/j.eururo.2015.11.036

Loeb, S., Shin, S. S., Broyles, D. L., Wei, J. T., Sanda, M., Klee, G., . . . Catalona, W. J. (2017). Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int, 120(1), 61-68. doi:10.1111/bju.13676

Lorente, D., Omlin, A., Ferraldeschi, R., Pezaro, C., Perez, R., Mateo, J., . . . Attard, G. (2014). Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer, 111(12), 2248-2253. doi:10.1038/bjc.2014.531

Luboldt, H. J., Schindler, J. F., & Rubben, H. (2007). Age-specific Ranges for Prostate-Specific Antigen as a Marker for Prostate Cancer. EAU-EBU update Series 5 38-48.

Lumen, N., Ost, P., Van Praet, C., De Meerleer, G., Villeirs, G., & Fonteyne, V. (2013). Developments in external beam radiotherapy for prostate cancer. Urology, 82(1), 5-10. doi:10.1016/j.urology.2013.03.043

Lundstrom, K. J., Drevin, L., Carlsson, S., Garmo, H., Loeb, S., Stattin, P., & Bill-Axelson, A. (2014). Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol, 192(4), 1116-1122. doi:10.1016/j.juro.2014.04.098

Mahmud, S. M., Franco, E. L., & Aprikian, A. G. (2010). Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer, 127(7), 1680-1691. doi:10.1002/ijc.25186

Malekzadeh, F., Rose, C., Ingvar, C., & Jernstrom, H. (2005). [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]. Lakartidningen, 102(44), 3226-3228, 3230-3221.

Mandair, D., Rossi, R. E., Pericleous, M., Whyand, T., & Caplin, M. E. (2014). Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab (Lond), 11, 30. doi:10.1186/1743-7075-11-30

Marks, L. S., Andriole, G. L., Fitzpatrick, J. M., Schulman, C. C., & Roehrborn, C. G. (2006). The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol, 176(3), 868-874. doi:10.1016/j.juro.2006.04.024

Martinez-Monge, R., Moreno, M., Ciervide, R., Cambeiro, M., Perez-Gracia, J. L., Gil-Bazo, I., . . . Aristu, J. (2012). External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys, 82(3), e469-476. doi:10.1016/j.ijrobp.2011.08.002

Masko, E. M., Allott, E. H., & Freedland, S. J. (2013). The relationship between nutrition and prostate cancer: is more always better? Eur Urol, 63(5), 810-820. doi:10.1016/j.eururo.2012.11.012

Matei, D. V., Renne, G., Pimentel, M., Sandri, M. T., Zorzino, L., Botteri, E., . . . de Cobelli, O. (2012). Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer, 10(3), 164-173. doi:10.1016/j.clgc.2011.12.004

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., . . . de Bono, J. S. (2015). DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med, 373(18), 1697-1708. doi:10.1056/NEJMoa1506859

Matheson, L., Watson, E. K., Nayoan, J., Wagland, R., Glaser, A., Gavin, A., . . . Rivas, C. (2017). A qualitative metasynthesis exploring the impact of prostate cancer and its management on younger, unpartnered and gay men. Eur J Cancer Care (Engl), 26(6). doi:10.1111/ecc.12676

Matsushita, K., Tal, R., & Mulhall, J. P. (2012). The evolution of orgasmic pain (dysorgasmia) following radical prostatectomy. J Sex Med, 9(5), 1454-1458. doi:10.1111/j.1743-6109.2012.02699.x

Maughan, B. L., & Antonarakis, E. S. (2015). Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother, 16(10), 1521-1537. doi:10.1517/14656566.2015.1055249

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. (2000). Lancet, 355(9214), 1491-1498.

McLeod, D. G., Iversen, P., See, W. A., Morris, T., Armstrong, J., Wirth, M. P., & Casodex Early Prostate Cancer Trialists, G. (2006). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int, 97(2), 247-254. doi:10.1111/j.1464-410X.2005.06051.x

Mendenhall, W. M., Henderson, R. H., Indelicato, D. J., Keole, S. R., & Mendenhall, N. P. (2009). Erectile dysfunction after radiotherapy for prostate cancer. Am J Clin Oncol, 32(4), 443-447. doi:10.1097/COC.0b013e318173a563

Mertan, F. V., Greer, M. D., Shih, J. H., George, A. K., Kongnyuy, M., Muthigi, A., . . . Turkbey, B. (2016). Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. J Urol. doi:10.1016/j.juro.2016.04.057

Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., . . . Eastern Cooperative Oncology Group study, E. S. T. (2006). Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol, 7(6), 472-479. doi:10.1016/S1470-2045(06)70700-8

Mikah, P., Krabbe, L. M., Eminaga, O., Herrmann, E., Papavassilis, P., Hinkelammert, R., . . . Boegemann, M. (2016). Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer, 16(1), 214. doi:10.1186/s12885-016-2260-y

Mikkola, A., Aro, J., Rannikko, S., Ruutu, M., & Finnprostate, G. (2007). Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate, 67(4), 447-455. doi:10.1002/pros.20547

Mir, M. C., Li, J., Klink, J. C., Kattan, M. W., Klein, E. A., & Stephenson, A. J. (2014). Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol, 66(2), 204-210. doi:10.1016/j.eururo.2013.08.022

Moreira, D. M., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., Cooperberg, M. R., . . . Freedland, S. J. (2014). Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer, 120(2), 197-204. doi:10.1002/cncr.28423

Morikawa, L. K., & Roach, M., 3rd. (2011). Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys, 80(1), 6-16. doi:10.1016/j.ijrobp.2010.11.074

Morote, J., Trilla, E., Esquena, S., Serrallach, F., Abascal, J. M., Munoz, A., . . . de Torres, I. M. (2002). The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. Eur Urol, 42(4), 333-337.

Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., . . . Murray, N. (2017). Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys, 98(2), 275-285. doi:10.1016/j.ijrobp.2016.11.026

Mottet, N., Peneau, M., Mazeron, J. J., Molinie, V., & Richaud, P. (2012). Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol, 62(2), 213-219. doi:10.1016/j.eururo.2012.03.053

Moul, J. W., Wu, H., Sun, L., McLeod, D. G., Amling, C., Donahue, T., . . . Soderdahl, D. (2004). Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol, 171(3), 1141-1147. doi:10.1097/01.ju.0000113794.34810.d0

Mouraviev, V., Spiess, P. E., & Jones, J. S. (2012). Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol, 61(6), 1204-1211. doi:10.1016/j.eururo.2012.02.051

Muller, A. C., Lutjens, J., Alber, M., Eckert, F., Bamberg, M., Schilling, D., . . . Ganswindt, U. (2012). Toxicity and outcome of pelvic IMRT for node-positive prostate cancer. Strahlenther Onkol, 188(11), 982-989. doi:10.1007/s00066-012-0169-1

Muller, B. G., Shih, J. H., Sankineni, S., Marko, J., Rais-Bahrami, S., George, A. K., . . . Turkbey, B. (2015). Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 277(3), 741-750. doi:10.1148/radiol.2015142818

Mundy, A. R., & Andrich, D. E. (2012). Posterior urethral complications of the treatment of prostate cancer. BJU Int, 110(3), 304-325. doi:10.1111/j.1464-410X.2011.10864.x

Mydin, A. R., Dunne, M. T., Finn, M. A., & Armstrong, J. G. (2013). Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01. Int J Radiat Oncol Biol Phys, 85(1), 101-108. doi:10.1016/j.ijrobp.2012.03.001

Nanda, A., Chen, M. H., Moran, B. J., Braccioforte, M. H., Dosoretz, D., Salenius, S., . . . D'Amico, A. V. (2010). Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys, 76(5), 1439-1444. doi:10.1016/j.ijrobp.2009.03.034

Natarajan, S., Raman, S., Priester, A. M., Garritano, J., Margolis, D. J., Lieu, P., . . . Marks, L. S. (2016). Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. J Urol, 196(1), 68-75. doi:10.1016/j.juro.2015.12.083

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Newton, R. U., Jeffery, E., Galvao, D. A., Peddle-McIntyre, C. J., Spry, N., Joseph, D., . . . Taaffe, D. R. (2018). Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy. BJU Int, 122(6), 986-993. doi:10.1111/bju.14384

Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess, 19(87), i-xxxi, 1-191. doi:10.3310/hta19870

Nilsson, A. E., Schumacher, M. C., Johansson, E., Carlsson, S., Stranne, J., Nyberg, T., . . . Steineck, G. (2011). Age at surgery, educational level and long-term urinary incontinence after radical prostatectomy. BJU Int, 108(10), 1572-1577. doi:10.1111/j.1464-410X.2011.10231.x

Nordstrom, T., Akre, O., Aly, M., Gronberg, H., & Eklund, M. (2018). Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis, 21(1), 57-63. doi:10.1038/s41391-017-0024-7

Novara, G., Ficarra, V., Mocellin, S., Ahlering, T. E., Carroll, P. R., Graefen, M., . . . Wilson, T. G. (2012). Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol, 62(3), 382-404. doi:10.1016/j.eururo.2012.05.047

Novara, G., Ficarra, V., Rosen, R. C., Artibani, W., Costello, A., Eastham, J. A., . . . Wilson, T. G. (2012). Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol, 62(3), 431-452. doi:10.1016/j.eururo.2012.05.044

Nyberg, T., Govindasami, K., Leslie, G., Dadaev, T., Bancroft, E., Ni Raghallaigh, H., . . . Antoniou, A. C. (2019). Homeobox B13 G84E Mutation and Prostate Cancer Risk. Eur Urol, 75(5), 834-845. doi:10.1016/j.eururo.2018.11.015

O'Farrell, S., Garmo, H., Holmberg, L., Adolfsson, J., Stattin, P., & Van Hemelrijck, M. (2015). Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol, 33(11), 1243-1251. doi:10.1200/JCO.2014.59.1792

O'Neil, B. B., Presson, A., Gannon, J., Stephenson, R. A., Lowrance, W., Dechet, C. B., . . . Brant, W. O. (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-163. doi:10.1016/j.juro.2013.06.122

Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A., & Lieber, M. M. (1993). Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. Jama, 270(7), 860-864.

Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A., Aljadeed, R., Alsowaida, Y., . . . Abraham, I. (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate, 79(8), 880-895. doi:10.1002/pros.23795

Oliai, C., Fisher, B., Jani, A., Wong, M., Poli, J., Brady, L. W., & Komarnicky, L. T. (2012). Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys, 84(3), 733-740. doi:10.1016/j.ijrobp.2011.12.056

Orsted, D. D., Bojesen, S. E., Kamstrup, P. R., & Nordestgaard, B. G. (2013). Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. Eur Urol, 64(3), 384-393. doi:10.1016/j.eururo.2013.01.028

Oscarsson, N., Arnell, P., Lodding, P., Ricksten, S. E., & Seeman-Lodding, H. (2013). Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol Biol Phys, 87(4), 670-675. doi:10.1016/j.ijrobp.2013.07.039

Oscarsson, N., Muller, B., Rosen, A., Lodding, P., Molne, J., Giglio, D., . . . Seeman-Lodding, H. (2019). Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. doi:10.1016/s1470-2045(19)30494-2

Oudard, S., Fizazi, K., Sengelov, L., Daugaard, G., Saad, F., Hansen, S., . . . Sartor, O. (2017). Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol, 35(28), 3189-3197. doi:10.1200/JCO.2016.72.1068

Ouzaid, I., Xylinas, E., Ploussard, G., Hoznek, A., Vordos, D., Abbou, C. C., . . . Salomon, L. (2012). Anastomotic stricture after minimally invasive radical prostatectomy: what should be expected from the Van Velthoven single-knot running suture? J Endourol, 26(8), 1020-1025. doi:10.1089/end.2011.0650

Panebianco, V., Barchetti, G., Simone, G., Del Monte, M., Ciardi, A., Grompone, M. D., . . . Catalano, C. (2018). Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? Eur Urol, 74(1), 48-54. doi:10.1016/j.eururo.2018.03.007

Parekh, A., Graham, P. L., & Nguyen, P. L. (2013). Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol, 23(3), 222-234. doi:10.1016/j.semradonc.2013.01.006

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., . . . Investigators, A. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 369(3), 213-223. doi:10.1056/NEJMoa1213755

Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., . . . Sydes, M. R. (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), 2353-2366. doi:10.1016/s0140-6736(18)32486-3

Partin, A. W., Van Neste, L., Klein, E. A., Marks, L. S., Gee, J. R., Troyer, D. A., . . . Epstein, J. I. (2014). Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol, 192(4), 1081-1087. doi:10.1016/j.juro.2014.04.013

Pasoglou, V., Larbi, A., Collette, L., Annet, L., Jamar, F., Machiels, J. P., . . . Lecouvet, F. E. (2014). One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach? Prostate, 74(5), 469-477. doi:10.1002/pros.22764

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., . . . Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-648. doi:10.1016/S0140-6736(05)66954-1

Patientlag 2014:821 Kap 2-9.

Peach, M. S., Trifiletti, D. M., & Libby, B. (2016). Systematic Review of Focal Prostate Brachytherapy and the Future Implementation of Image-Guided Prostate HDR Brachytherapy Using MR-Ultrasound Fusion. Prostate Cancer, 2016, 4754031. doi:10.1155/2016/4754031

Peinemann, F., Grouven, U., Bartel, C., Sauerland, S., Borchers, H., Pinkawa, M., . . . Lange, S. (2011). Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol, 60(5), 881-893. doi:10.1016/j.eururo.2011.06.044

Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., . . . Lawrentschuk, N. (2016). Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol, 70(6), 926-937. doi:10.1016/j.eururo.2016.06.021

Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., . . . Murphy, D. G. (2019). Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. doi:10.1016/j.eururo.2019.01.049

Peterson, C. (2005). [Natural remedies--self care at your own risk! Danger of unknown adverse effects and interactions with "common" medications]. Lakartidningen, 102(44), 3200-3201.

Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., . . . Crawford, E. D. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351(15), 1513-1520. doi:10.1056/NEJMoa041318

Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., . . . Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys, 61(5), 1285-1290. doi:10.1016/j.ijrobp.2004.08.047

Pisansky, T. M., Hunt, D., Gomella, L. G., Amin, M. B., Balogh, A. G., Chinn, D. M., . . . Sandler, H. M. (2015). Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol, 33(4), 332-339. doi:10.1200/JCO.2014.58.0662

Popiolek, M., Rider, J. R., Andren, O., Andersson, S. O., Holmberg, L., Adami, H. O., & Johansson, J. E. (2013). Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol, 63(3), 428-435. doi:10.1016/j.eururo.2012.10.002

Poulsen, M. H., Petersen, H., Hoilund-Carlsen, P. F., Jakobsen, J. S., Gerke, O., Karstoft, J., . . . Walter, S. (2014). Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int, 114(6), 818-823. doi:10.1111/bju.12599

Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., & Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. Jama, 281(17), 1591-1597.

Preston, M. A., Batista, J. L., Wilson, K. M., Carlsson, S. V., Gerke, T., Sjoberg, D. D., . . . Mucci, L. A. (2016). Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol, 34(23), 2705-2711. doi:10.1200/jco.2016.66.7527

Preston, M. A., Wilson, K. M., Markt, S. C., Ge, R., Morash, C., Stampfer, M. J., . . . Olumi, A. F. (2014). 5alpha-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med, 174(8), 1301-1307. doi:10.1001/jamainternmed.2014.1600

Prota, C., Gomes, C. M., Ribeiro, L. H., de Bessa, J., Jr., Nakano, E., Dall'Oglio, M., . . . Srougi, M. (2012). Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. Int J Impot Res, 24(5), 174-178. doi:10.1038/ijir.2012.11

Qin, F., Wang, S., Li, J., Wu, C., & Yuan, J. (2018). The Early Use of Vacuum Therapy for Penile Rehabilitation After Radical Prostatectomy: Systematic Review and Meta-Analysis. Am J Mens Health, 12(6), 2136-2143. doi:10.1177/1557988318797409

Rahbar, K., Boegemann, M., Yordanova, A., Eveslage, M., Schafers, M., Essler, M., & Ahmadzadehfar, H. (2018). PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging, 45(1), 12-19. doi:10.1007/s00259-017-3848-4

Rajan, P., Sooriakumaran, P., Nyberg, T., Akre, O., Carlsson, S., Egevad, L., . . . Wiklund, N. P. (2017). Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol, 35(31), 3566-3574. doi:10.1200/jco.2016.70.7794

Randazzo, M., Beatrice, J., Huber, A., Grobholz, R., Manka, L., Chun, F. K., . . . Kwiatkowski, M. (2015). A "PSA pyramid" for men with initial prostate-specific antigen </=3 ng/ml: a plea for individualized prostate cancer screening. Eur Urol, 68(4), 591-597. doi:10.1016/j.eururo.2014.04.005

Rao, K., Manya, K., Azad, A., Lawrentschuk, N., Bolton, D., Davis, I. D., & Sengupta, S. (2014). Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int, 114 Suppl 1, 50-54. doi:10.1111/bju.12764

Rhee, H., Gunter, J. H., Heathcote, P., Ho, K., Stricker, P., Corcoran, N. M., & Nelson, C. C. (2015). Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int, 115 Suppl 5, 3-13. doi:10.1111/bju.12964

Rider, J. R., Sandin, F., Andren, O., Wiklund, P., Hugosson, J., & Stattin, P. (2013). Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol, 63(1), 88-96. doi:10.1016/j.eururo.2012.08.001

Robinson, D., Garmo, H., Bill-Axelson, A., Mucci, L., Holmberg, L., & Stattin, P. (2013). Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ, 346, f3406. doi:10.1136/bmj.f3406

Robinson, D., Garmo, H., Lissbrant, I. F., Widmark, A., Pettersson, A., Gunnlaugsson, A., . . . Stattin, P. (2018). Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. Eur Urol, 73(4), 502-511. doi:10.1016/j.eururo.2017.11.039

Rodda, S., Tyldesley, S., Morris, W. J., Keyes, M., Halperin, R., Pai, H., . . . Murray, N. (2017). ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys, 98(2), 286-295. doi:10.1016/j.ijrobp.2017.01.008

Roed Nielsen, H., Petersen, J., Therkildsen, C., Skytte, A. B., & Nilbert, M. (2016). Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. Acta Oncol, 55(1), 38-44. doi:10.3109/0284186X.2015.1067714

Rogers, C. L., Alder, S. C., Rogers, R. L., Hopkins, S. A., Platt, M. L., Childs, L. C., . . . Hayes, J. K. (2012). High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol, 187(1), 109-116. doi:10.1016/j.juro.2011.09.050

Romero-Laorden, N., Lozano, R., Jayaram, A., Lopez-Campos, F., Saez, M. I., Montesa, A., . . . Olmos, D. (2018). Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer, 119(9), 1052-1059. doi:10.1038/s41416-018-0123-9

Romesser, P. B., Pei, X., Shi, W., Zhang, Z., Kollmeier, M., McBride, S. M., & Zelefsky, M. J. (2018). Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys, 100(1), 59-67. doi:10.1016/j.ijrobp.2017.09.003

Rosenkrantz, A. B., Ginocchio, L. A., Cornfeld, D., Froemming, A. T., Gupta, R. T., Turkbey, B., . . . Margolis, D. J. (2016). Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 280(3), 793-804. doi:10.1148/radiol.2016152542

Rosenthal, S. A., Hu, C., Sartor, O., Gomella, L. G., Amin, M. B., Purdy, J., . . . Sandler, H. M. (2019). Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol, 37(14), 1159-1168. doi:10.1200/jco.18.02158

Rosenthal, S. A., Hunt, D., Sartor, A. O., Pienta, K. J., Gomella, L., Grignon, D., . . . Sandler, H. (2015). A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys, 93(2), 294-302. doi:10.1016/j.ijrobp.2015.05.024

Ross, H. M., Kryvenko, O. N., Cowan, J. E., Simko, J. P., Wheeler, T. M., & Epstein, J. I. (2012). Do adenocarcinomas of the prostate with Gleason score (GS) </=6 have the potential to metastasize to lymph nodes? Am J Surg Pathol, 36(9), 1346-1352. doi:10.1097/PAS.0b013e3182556dcd

Rostaminia, G., Chang, C., Pincus, J. B., Sand, P. K., & Goldberg, R. P. (2018). Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. doi:10.1007/s00192-018-3834-9

Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31-41. doi:10.1016/S0140-6736(10)62110-1

Royce, T. J., & Efstathiou, J. A. (2019). Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. Urol Oncol, 37(9), 628-636. doi:10.1016/j.urolonc.2018.11.012

Russo, G. I., Regis, F., Castelli, T., Favilla, V., Privitera, S., Giardina, R., . . . Morgia, G. (2017). A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. Clin Genitourin Cancer, 15(4), 429-439 e421. doi:10.1016/j.clgc.2016.12.022

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F., Sternberg, C. N., . . . Investigators, C.-A.-. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16(2), 152-160. doi:10.1016/S1470-2045(14)71205-7

Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., . . . Zoledronic Acid Prostate Cancer Study, G. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst, 96(11), 879-882.

Salonia, A., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., . . . Khera, M. (2017a). Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med, 14(3), 285-296. doi:10.1016/j.jsxm.2016.11.325

Salonia, A., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., . . . Khera, M. (2017b). Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med, 14(3), 297-315. doi:10.1016/j.jsxm.2016.11.324

Samadder, N. J., Smith, K. R., Wong, J., Thomas, A., Hanson, H., Boucher, K., . . . Curtin, K. (2017). Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome. JAMA Oncol, 3(12), 1697-1701. doi:10.1001/jamaoncol.2017.0769

Samaratunga, H., Delahunt, B., Gianduzzo, T., Coughlin, G., Duffy, D., LeFevre, I., . . . Yaxley, J. (2015). The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology, 47(6), 515-519. doi:10.1097/PAT.0000000000000315

Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., . . . Wei, J. T. (2008). Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med, 358(12), 1250-1261. doi:10.1056/NEJMoa074311

Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., . . . Investigators, A. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367(13), 1187-1197. doi:10.1056/NEJMoa1207506

Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., . . . Armstrong, A. J. (2016). Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol, 34(12), 1402-1418. doi:10.1200/JCO.2015.64.2702

Schoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. (2015). Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol, 68(3), 438-450. doi:10.1016/j.eururo.2014.11.037

Schrader, A. J., Boegemann, M., Ohlmann, C. H., Schnoeller, T. J., Krabbe, L. M., Hajili, T., . . . Cronauer, M. V. (2014). Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol, 65(1), 30-36. doi:10.1016/j.eururo.2013.06.042

Schreiber, D., Chen, S. C., Rineer, J., Worth, M., Telivala, T., & Schwartz, D. (2014). Assessment of risk of late rectal bleeding for patients with prostate cancer started on anticoagulation before or after radiation treatment. Anticancer Res, 34(12), 7367-7372.

Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., . . . Investigators, E. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027-2035. doi:10.1016/S0140-6736(14)60525-0

Sella, A., Sternberg, C. N., Skoneczna, I., & Kovel, S. (2008). Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int, 102(11), 1607-1609. doi:10.1111/j.1464-410X.2008.07873.x

Selvadurai, E. D., Singhera, M., Thomas, K., Mohammed, K., Woode-Amissah, R., Horwich, A., . . . Parker, C. C. (2013). Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol, 64(6), 981-987. doi:10.1016/j.eururo.2013.02.020

Serretta, V., Altieri, V., Morgia, G., Nicolosi, F., De Grande, G., Mazza, R., . . . Gebbia, V. (2012). A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer, 10(3), 174-179. doi:10.1016/j.clgc.2012.03.002

Shariff, A. H., & Ather, M. H. (2006). Neuroendocrine differentiation in prostate cancer. Urology, 68(1), 2-8. doi:10.1016/j.urology.2006.02.002

Shelley, M. D., Kumar, S., Wilt, T., Staffurth, J., Coles, B., & Mason, M. D. (2009). A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev, 35(1), 9-17. doi:10.1016/j.ctrv.2008.08.002

Shen, G., Deng, H., Hu, S., & Jia, Z. (2014). Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol, 43(11), 1503-1513. doi:10.1007/s00256-014-1903-9

Shikanov, S., Song, J., Royce, C., Al-Ahmadie, H., Zorn, K., Steinberg, G., . . . Eggener, S. (2009). Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol, 182(1), 139-144. doi:10.1016/j.juro.2009.02.139

Shim, M., Kim, J., Park, S., Choi, S. K., Lee, S. M., Huh, K. O., . . . Ahn, H. (2015). The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology, 85(5), 1123-1129. doi:10.1016/j.urology.2015.01.022

Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., . . . RTOG, N. R. G. O. (2017). Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med, 376(5), 417-428. doi:10.1056/NEJMoa1607529

Siddiqui, S. A., Boorjian, S. A., Inman, B., Bagniewski, S., Bergstralh, E. J., & Blute, M. L. (2008). Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol, 179(5), 1830-1837; discussion 1837. doi:10.1016/j.juro.2008.01.022

Smith, J. B., Popert, R., Nuttall, M. C., Vyas, L., Kinsella, J., & Cahill, D. (2014). Transperineal sector prostate biopsies: a local anesthetic outpatient technique. Urology, 83(6), 1344-1349. doi:10.1016/j.urology.2014.02.008

Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., . . . Higano, C. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20(3), 408-419. doi:10.1016/s1470-2045(18)30860-x

Smith, M. R., Cook, R., Lee, K. A., & Nelson, J. B. (2011). Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer, 117(10), 2077-2085. doi:10.1002/cncr.25762

Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., . . . Higano, C. S. (2005). Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol, 23(13), 2918-2925. doi:10.1200/JCO.2005.01.529

Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., . . . Small, E. J. (2018). Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med, 378(15), 1408-1418. doi:10.1056/NEJMoa1715546

Smith, M. R., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., . . . Goessl, C. (2013). Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol, 31(30), 3800-3806. doi:10.1200/JCO.2012.44.6716

Soeterik, T. F. W., van Melick, H. H. E., Dijksman, L. M., Biesma, D. H., Witjes, J. A., & van Basten, J. A. (2019). Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients. Eur Urol Oncol, 2(5), 483-489. doi:10.1016/j.euo.2019.01.010

Solberg et al: Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.

Sooriakumaran, P., Haendler, L., Nyberg, T., Gronberg, H., Nilsson, A., Carlsson, S., . . . Wiklund, P. (2012). Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol, 62(5), 768-774. doi:10.1016/j.eururo.2012.05.024

Sooriakumaran, P., Nyberg, T., Akre, O., Haendler, L., Heus, I., Olsson, M., . . . Wiklund, P. (2014). Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ, 348, g1502. doi:10.1136/bmj.g1502

Sooriakumaran, P., Ploumidis, A., Nyberg, T., Olsson, M., Akre, O., Haendler, L., . . . Wiklund, P. (2015). The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years. BJU Int, 115(1), 106-113. doi:10.1111/bju.12483

Srigley, J. R., Humphrey, P. A., Amin, M. B., Chang, S. S., Egevad, L., Epstein, J. I., . . . Members of the Cancer Committee, C. o. A. P. (2009). Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med, 133(10), 1568-1576. doi:10.1043/1543-2165-133.10.1568

Stattin, P., Holmberg, E., Johansson, J. E., Holmberg, L., Adolfsson, J., Hugosson, J., & National Prostate Cancer Register of, S. (2010). Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst, 102(13), 950-958. doi:10.1093/jnci/djq154

Steentjes, L., Siesling, S., Drummond, F. J., van Manen, J. G., Sharp, L., & Gavin, A. (2016). Factors associated with current and severe physical side-effects after prostate cancer treatment: What men report. Eur J Cancer Care (Engl). doi:10.1111/ecc.12589

Steineck, G., Bjartell, A., Hugosson, J., Axen, E., Carlsson, S., Stranne, J., . . . committee, L. s. (2015). Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. Eur Urol, 67(3), 559-568. doi:10.1016/j.eururo.2014.10.011

Steinsvik, E. A., Axcrona, K., Angelsen, A., Beisland, C., Dahl, A., Eri, L. M., . . . Fossa, S. (2013). Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study. Scand J Urol, 47(2), 92-100. doi:10.3109/00365599.2012.707684

Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., . . . Pollack, A. (2007). Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol, 25(15), 2035-2041. doi:10.1200/JCO.2006.08.9607

Stock, R. G., Berkowitz, J., Blacksburg, S. R., & Stone, N. N. (2012). Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure. BJU Int, 110(9), 1257-1261. doi:10.1111/j.1464-410X.2012.11057.x

Stor variation i kostråden vid strålbehandling av lilla bäckenet. 2018;115:FALY Retrieved from https://lakartidningen.se/Klinik-och-vetenskap/Originalstudie/2018/10/Stor-variation-i-kostraden-vid-stralbehandling-av-lilla-backenet/

Strom, P., Nordstrom, T., Aly, M., Egevad, L., Gronberg, H., & Eklund, M. (2018). The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol, 74(2), 204-210. doi:10.1016/j.eururo.2017.12.028

Studer, U. E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., . . . Group, E. G. (2008). Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol, 53(5), 941-949. doi:10.1016/j.eururo.2007.12.032

Suardi, N., Gandaglia, G., Gallina, A., Di Trapani, E., Scattoni, V., Vizziello, D., . . . Briganti, A. (2015). Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol, 67(2), 299-309. doi:10.1016/j.eururo.2014.02.011

Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737-746. doi:10.1056/NEJMoa1503747

Sydes, M. R., Spears, M. R., Mason, M. D., Clarke, N. W., Dearnaley, D. P., de Bono, J. S., . . . James, N. D. (2018). Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol, 29(5), 1235-1248. doi:10.1093/annonc/mdy072

Sylvester, J. E., Grimm, P. D., Blasko, J. C., Millar, J., Orio, P. F., 3rd, Skoglund, S., . . . Merrick, G. (2007). 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys, 67(1), 57-64. doi:10.1016/j.ijrobp.2006.07.1382

Taylor, J. A., 3rd, Koff, S. G., Dauser, D. A., & McLeod, D. G. (2006). The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int, 98(3), 540-543. doi:10.1111/j.1464-410X.2006.06294.x

Taylor, R. A., Fraser, M., Livingstone, J., Espiritu, S. M., Thorne, H., Huang, V., . . . Bristow, R. G. (2017). Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun, 8, 13671. doi:10.1038/ncomms13671

Thoeny, H. C., Froehlich, J. M., Triantafyllou, M., Huesler, J., Bains, L. J., Vermathen, P., . . . Studer, U. E. (2014). Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology, 273(1), 125-135. doi:10.1148/radiol.14132921

Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., . . . Coltman, C. A., Jr. (2006). Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst, 98(16), 1128-1133. doi:10.1093/jnci/djj307

Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., . . . Coltman, C. A., Jr. (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med, 349(3), 215-224. doi:10.1056/NEJMoa030660

Thompson, I. M., Jr., Goodman, P. J., Tangen, C. M., Parnes, H. L., Minasian, L. M., Godley, P. A., . . . Ford, L. G. (2013). Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med, 369(7), 603-610. doi:10.1056/NEJMoa1215932

Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., . . . Crawford, E. D. (2009). Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol, 181(3), 956-962. doi:10.1016/j.juro.2008.11.032

Thomsen, F. B., Brasso, K., Christensen, I. J., Johansson, J. E., Angelsen, A., Tammela, T. L., . . . Scandinavian Prostate Cancer, G. (2015). Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer, 51(10), 1283-1292. doi:10.1016/j.ejca.2015.03.021

Thromboprophylaxis. Retrieved from https://uroweb.org/guideline/thromboprophylaxis/

Tombal, B., Miller, K., Boccon-Gibod, L., Schroder, F., Shore, N., Crawford, E. D., . . . Persson, B. E. (2010). Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol, 57(5), 836-842. doi:10.1016/j.eururo.2009.11.029

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., . . . Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366(26), 2443-2454. doi:10.1056/NEJMoa1200690

Tosoian, J. J., Alam, R., Ball, M. W., Carter, H. B., & Epstein, J. I. (2018). Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nat Rev Urol, 15(1), 55-66. doi:10.1038/nrurol.2017.134

Tosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Macura, K. J., Simopoulos, D. N., . . . Gorin, M. A. (2020). Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. doi:10.1016/j.eururo.2019.12.017

Touijer, K. A., Mazzola, C. R., Sjoberg, D. D., Scardino, P. T., & Eastham, J. A. (2014). Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol, 65(1), 20-25. doi:10.1016/j.eururo.2013.03.053

Trinh, Q. D., Bjartell, A., Freedland, S. J., Hollenbeck, B. K., Hu, J. C., Shariat, S. F., . . . Vickers, A. J. (2013). A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol, 64(5), 786-798. doi:10.1016/j.eururo.2013.04.012

Trpkov, K., Yilmaz, A., Bismar, T. A., & Montironi, R. (2010). 'Insignificant' prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme 'low-volume/low-grade' prostate cancer? BJU Int, 106(3), 304-315. doi:10.1111/j.1464-410X.2010.09499.x

Tsaur, I., Heidegger, I., Kretschmer, A., Borgmann, H., Gandaglia, G., Briganti, A., . . . Surcel, C. (2019). Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? Cancer Treat Rev, 75, 20-26. doi:10.1016/j.ctrv.2019.03.001

Tselis, N., Hoskin, P., Baltas, D., Strnad, V., Zamboglou, N., Rodel, C., & Chatzikonstantinou, G. (2017). High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status. Clin Oncol (R Coll Radiol), 29(7), 401-411. doi:10.1016/j.clon.2017.02.015

Tyritzis, S. I., Wallerstedt, A., Steineck, G., Nyberg, T., Hugosson, J., Bjartell, A., . . . Committee, L. S. (2015). Thromboembolic complications in 3,544 patients undergoing radical prostatectomy with or without lymph node dissection. J Urol, 193(1), 117-125. doi:10.1016/j.juro.2014.08.091

Tyrrell, C. J., Kaisary, A. V., Iversen, P., Anderson, J. B., Baert, L., Tammela, T., . . . Blackledge, G. (1998). A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 33(5), 447-456.

Tyrrell, C. J., Payne, H., Tammela, T. L., Bakke, A., Lodding, P., Goedhals, L., . . . Carroll, K. (2004). Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys, 60(2), 476-483. doi:10.1016/j.ijrobp.2004.03.022

Umbehr, M. H., Muntener, M., Hany, T., Sulser, T., & Bachmann, L. M. (2013). The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol, 64(1), 106-117. doi:10.1016/j.eururo.2013.04.019

Urological Infections. Retrieved from https://uroweb.org/guideline/urological-infections/

Uth, J., Hornstrup, T., Christensen, J. F., Christensen, K. B., Jorgensen, N. R., Schmidt, J. F., . . . Helge, E. W. (2016). Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Osteoporos Int, 27(4), 1507-1518. doi:10.1007/s00198-015-3399-0

Valdagni, R., Albers, P., Bangma, C., Drudge-Coates, L., Magnani, T., Moynihan, C., . . . Costa, A. (2011). The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer, 47(1), 1-7. doi:10.1016/j.ejca.2010.10.029

Valerio, M., Cerantola, Y., Eggener, S. E., Lepor, H., Polascik, T. J., Villers, A., & Emberton, M. (2017). New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol, 71(1), 17-34. doi:10.1016/j.eururo.2016.08.044

Wallerstedt, A., Carlsson, S., Steineck, G., Thorsteinsdottir, T., Hugosson, J., Stranne, J., . . . Wiklund, N. P. (2013). Patient and tumour-related factors for prediction of urinary incontinence after radical prostatectomy. Scand J Urol, 47(4), 272-281. doi:10.3109/00365599.2012.733410

Wallerstedt, A., Tyritzis, S. I., Thorsteinsdottir, T., Carlsson, S., Stranne, J., Gustafsson, O., . . . committee, L. s. (2015). Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. Eur Urol, 67(4), 660-670. doi:10.1016/j.eururo.2014.09.036

Wallis, C. J. D., Klaassen, Z., Bhindi, B., Goldberg, H., Chandrasekar, T., Farrell, A. M., . . . Satkunasivam, R. (2018). Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol, 73(6), 834-844. doi:10.1016/j.eururo.2017.10.002

Van der Kwast, T. H., Bolla, M., Van Poppel, H., Van Cangh, P., Vekemans, K., Da Pozzo, L., . . . Eortc. (2007). Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol, 25(27), 4178-4186. doi:10.1200/JCO.2006.10.4067

Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., . . . Schalken, J. A. (2016). Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol, 70(5), 740-748. doi:10.1016/j.eururo.2016.04.012

van Oort, I. M., Bruins, H. M., Kiemeney, L. A., Knipscheer, B. C., Witjes, J. A., & Hulsbergen-van de Kaa, C. A. (2010). The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. Histopathology, 56(4), 464-471. doi:10.1111/j.1365-2559.2010.03497.x

Wang, H. T., Yao, Y. H., Li, B. G., Tang, Y., Chang, J. W., & Zhang, J. (2014). Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol, 32(30), 3383-3390. doi:10.1200/JCO.2013.54.3553

Varma, M., Delahunt, B., Egevad, L., Samaratunga, H., & Kristiansen, G. (2019). Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Arch, 474(5), 525-534. doi:10.1007/s00428-019-02544-6

Washino, S., Okochi, T., Saito, K., Konishi, T., Hirai, M., Kobayashi, Y., & Miyagawa, T. (2017). Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int, 119(2), 225-233. doi:10.1111/bju.13465

Watkins Bruner, D., James, J. L., Bryan, C. J., Pisansky, T. M., Rotman, M., Corbett, T., . . . Berk, L. (2011). Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med, 8(4), 1228-1238. doi:10.1111/j.1743-6109.2010.02164.x

Weiner, J. P., Wong, A. T., Schwartz, D., Martinez, M., Aytaman, A., & Schreiber, D. (2016). Endoscopic and non-endoscopic approaches for the management of radiation-induced rectal bleeding. World J Gastroenterol, 22(31), 6972-6986. doi:10.3748/wjg.v22.i31.6972

Vellekoop, A., Loeb, S., Folkvaljon, Y., & Stattin, P. (2014). Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol, 191(2), 350-357. doi:10.1016/j.juro.2013.09.034

Venderink, W., van Luijtelaar, A., Bomers, J. G., van der Leest, M., Hulsbergen-van de Kaa, C., Barentsz, J. O., . . . Futterer, J. J. (2017). Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. Eur Urol. doi:10.1016/j.eururo.2017.02.021

Venkitaraman, R., Cook, G. J., Dearnaley, D. P., Parker, C. C., Huddart, R. A., Khoo, V., . . . Sohaib, S. A. (2009). Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? Clin Oncol (R Coll Radiol), 21(1), 39-42. doi:10.1016/j.clon.2008.09.006

Venkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., . . . Parker, C. (2015). A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol, 67(4), 673-679. doi:10.1016/j.eururo.2014.10.004

Venkitaraman, R., Norman, A., Woode-Amissah, R., Fisher, C., Dearnaley, D., Horwich, A., . . . Parker, C. (2007). Predictors of histological disease progression in untreated, localized prostate cancer. J Urol, 178(3 Pt 1), 833-837. doi:10.1016/j.juro.2007.05.038

Wennick, A., Jonsson, A. K., Bratt, O., & Stenzelius, K. (2017). Everyday life after a radical prostatectomy - A qualitative study of men under 65 years of age. Eur J Oncol Nurs, 30, 107-112. doi:10.1016/j.ejon.2017.08.008

Wenske, S., Quarrier, S., & Katz, A. E. (2013). Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Eur Urol, 64(1), 1-7. doi:10.1016/j.eururo.2012.07.008

Ventimiglia, E., Folkvaljon, Y., Carlsson, S., Bratt, O., Montorsi, F., Volz, D., . . . Stattin, P. (2018). Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. J Surg Oncol, 117(2), 321-327. doi:10.1002/jso.24816

White, I. D., Wilson, J., Aslet, P., Baxter, A. B., Birtle, A., Challacombe, B., . . . Kirby, M. (2015). Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract, 69(1), 106-123. doi:10.1111/ijcp.12512

Whiting, J., Sano, T., Saka, M., Fukagawa, T., Katai, H., & Sasako, M. (2006). Follow-up of gastric cancer: a review. Gastric Cancer, 9(2), 74-81. doi:10.1007/s10120-006-0360-0

Viani, G. A., Stefano, E. J., & Afonso, S. L. (2009). Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys, 74(5), 1405-1418. doi:10.1016/j.ijrobp.2008.10.091

Vickers, A. J., Cronin, A. M., Bjork, T., Manjer, J., Nilsson, P. M., Dahlin, A., . . . Lilja, H. (2010). Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ, 341, c4521. doi:10.1136/bmj.c4521

Vickers, A. J., Ulmert, D., Sjoberg, D. D., Bennette, C. J., Bjork, T., Gerdtsson, A., . . . Lilja, H. (2013). Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ, 346, f2023. doi:10.1136/bmj.f2023

Widmark, A., Fossa, S. D., Lundmo, P., Damber, J. E., Vaage, S., Damber, L., . . . Klepp, O. (2003). Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology, 61(1), 145-151.

Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., . . . Nilsson, P. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet, 394(10196), 385-395. doi:10.1016/s0140-6736(19)31131-6

Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., . . . Swedish Association for Urological, O. (2009). Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet, 373(9660), 301-308. doi:10.1016/S0140-6736(08)61815-2

Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, R., Storkel, S., . . . Miller, K. (2009). Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 27(18), 2924-2930. doi:10.1200/JCO.2008.18.9563

Wilder, R. B., Barme, G. A., Gilbert, R. F., Holevas, R. E., Kobashi, L. I., Reed, R. R., . . . Tokita, K. M. (2010). Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. Brachytherapy, 9(4), 341-348. doi:10.1016/j.brachy.2009.08.003

Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., Kim, S. H., & Moon, M. H. (2018). Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 211(5), W226-w241. doi:10.2214/ajr.18.19880

Wortel, R. C., Pos, F. J., Heemsbergen, W. D., & Incrocci, L. (2016). Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial. J Sex Med, 13(11), 1695-1703. doi:10.1016/j.jsxm.2016.08.012

Yamamoto, Y., Offord, C. P., Kimura, G., Kuribayashi, S., Takeda, H., Tsuchiya, S., . . . Dingli, D. (2016). Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer, 115(2), 195-202. doi:10.1038/bjc.2016.171

Yoshioka, Y., Konishi, K., Sumida, I., Takahashi, Y., Isohashi, F., Ogata, T., . . . Inoue, T. (2011). Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys, 80(2), 469-475. doi:10.1016/j.ijrobp.2010.02.013

Yoshioka, Y., Kotsuma, T., Komiya, A., Kariya, S., Konishi, K., Nonomura, N., . . . Itami, J. (2017). Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys, 97(5), 952-961. doi:10.1016/j.ijrobp.2016.12.013

Yu, H., Yin, L., Jiang, X., Sun, X., Wu, J., Tian, H., . . . He, X. (2014). Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One, 9(12), e116327. doi:10.1371/journal.pone.0116327

Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014). Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol, 32(1), 5-11. doi:10.1200/JCO.2013.49.4757

Zafeiriou, Z., Jayaram, A., Sharp, A., & de Bono, J. S. (2016). Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Drugs, 76(4), 421-430. doi:10.1007/s40265-015-0530-7

Zapatero, A., Guerrero, A., Maldonado, X., Alvarez, A., Gonzalez San Segundo, C., Cabeza Rodriguez, M. A., . . . Calvo, F. A. (2015). High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol, 16(3), 320-327. doi:10.1016/S1470-2045(15)70045-8

Zelefsky, M. J., Ben-Porat, L., Scher, H. I., Chan, H. M., Fearn, P. A., Fuks, Z. Y., . . . Venkatraman, E. S. (2005). Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol, 23(4), 826-831. doi:10.1200/JCO.2005.02.111

Zhang, J., Xiao, L., Qin, Z., Xu, A., Zhao, K., Liang, C., . . . Wang, Z. (2016). Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis. Oncotarget, 7(41), 67101-67110. doi:10.18632/oncotarget.11937

Zumsteg, Z. S., Spratt, D. E., Pei, I., Zhang, Z., Yamada, Y., Kollmeier, M., & Zelefsky, M. J. (2013). A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol, 64(6), 895-902. doi:10.1016/j.eururo.2013.03.033

Zumsteg, Z. S., Spratt, D. E., Pei, X., Yamada, Y., Kalikstein, A., Kuk, D., . . . Zelefsky, M. J. (2013). Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys, 85(4), 1012-1017. doi:10.1016/j.ijrobp.2012.07.2374

Zwahlen, D. R., Andrianopoulos, N., Matheson, B., Duchesne, G. M., & Millar, J. L. (2010). High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy, 9(1), 27-35. doi:10.1016/j.brachy.2009.04.007

Nästa kapitel
23 Förslag på fördjupning